Literature DB >> 25245536

Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.

Petra Simon1, Tana A Omokoko1, Andrea Breitkreuz1, Lisa Hebich1, Sebastian Kreiter1, Sebastian Attig1, Abdo Konur2, Cedrik M Britten2, Claudia Paret3, Karl Dhaene4, Özlem Türeci5, Ugur Sahin6.   

Abstract

The determination of the epitope specificity of disease-associated T-cell responses is relevant for the development of biomarkers and targeted immunotherapies against cancer, autoimmune, and infectious diseases. The lack of known T-cell epitopes and corresponding T-cell receptors (TCR) for novel antigens hinders the efficient development and monitoring of new therapies. We developed an integrated approach for the systematic retrieval and functional characterization of TCRs from single antigen-reactive T cells that includes the identification of epitope specificity. This is accomplished through the rapid cloning of full-length TCR-α and TCR-β chains directly from single antigen-specific CD8(+) or CD4(+) T lymphocytes. The functional validation of cloned TCRs is conducted using in vitro-transcribed RNA transfer for expression of TCRs in T cells and HLA molecules in antigen-presenting cells. This method avoids the work and bias associated with repetitive cycles of in vitro T-cell stimulation, and enables fast characterization of antigen-specific T-cell responses. We applied this strategy to viral and tumor-associated antigens (TAA), resulting in the retrieval of 56 unique functional antigen-specific TCRs from human CD8(+) and CD4(+) T cells (13 specific for CMV-pp65, 16 specific for the well-known TAA NY-ESO-1, and 27 for the novel TAA TPTE), which are directed against 39 different epitopes. The proof-of-concept studies with TAAs NY-ESO-1 and TPTE revealed multiple novel TCR specificities. Our approach enables the rational development of immunotherapy strategies by providing antigen-specific TCRs and immunogenic epitopes. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245536     DOI: 10.1158/2326-6066.CIR-14-0108

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  14 in total

1.  Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain.

Authors:  Paul Nghiem; William W Kwok; David M Koelle; Natalie V Longino; Junbao Yang; Jayasri G Iyer; Dafina Ibrani; I-Ting Chow; Kerry J Laing; Victoria L Campbell; Kelly G Paulson; Rima M Kulikauskas; Candice D Church; Eddie A James
Journal:  Cancer Immunol Res       Date:  2019-08-12       Impact factor: 11.151

2.  Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

Authors:  Katy J McCann; Ann Mander; Angelica Cazaly; Lindsey Chudley; Jana Stasakova; Stephen Thirdborough; Andrew King; Paul Lloyd-Evans; Emily Buxton; Ceri Edwards; Sarah Halford; Andrew Bateman; Ann O'Callaghan; Sally Clive; Alan Anthoney; Duncan I Jodrell; Toni Weinschenk; Petra Simon; Ugur Sahin; Gareth J Thomas; Freda K Stevenson; Christian H Ottensmeier
Journal:  Clin Cancer Res       Date:  2016-04-18       Impact factor: 12.531

3.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Authors:  Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2016-06-01       Impact factor: 49.962

4.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

5.  Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants.

Authors:  Chao Hu; Meiying Shen; Xiaojian Han; Qian Chen; Luo Li; Siyin Chen; Jing Zhang; Fengxia Gao; Wang Wang; Yingming Wang; Tingting Li; Shenglong Li; Jingjing Huang; Jianwei Wang; Ju Zhu; Dan Chen; Qingchen Wu; Kun Tao; Da Pang; Aishun Jin
Journal:  Genes Dis       Date:  2021-06-29

Review 6.  Identification of neoantigens for individualized therapeutic cancer vaccines.

Authors:  Franziska Lang; Barbara Schrörs; Martin Löwer; Özlem Türeci; Ugur Sahin
Journal:  Nat Rev Drug Discov       Date:  2022-02-01       Impact factor: 112.288

7.  Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

Authors:  Tana Omokoko; Petra Simon; Özlem Türeci; Ugur Sahin
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

8.  Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.

Authors:  Tana A Omokoko; Uli Luxemburger; Shaheer Bardissi; Petra Simon; Magdalena Utsch; Andrea Breitkreuz; Özlem Türeci; Ugur Sahin
Journal:  J Immunol Res       Date:  2016-01-05       Impact factor: 4.818

Review 9.  The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.

Authors:  Zeming Mo; Peixin Du; Guoping Wang; Yongsheng Wang
Journal:  J Cancer       Date:  2017-06-23       Impact factor: 4.207

10.  CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.

Authors:  Claudia Paret; Petra Simon; Kirsten Vormbrock; Christian Bender; Anne Kölsch; Andrea Breitkreuz; Özlem Yildiz; Tana Omokoko; Stefanie Hubich-Rau; Christoph Hartmann; Sabine Häcker; Meike Wagner; Diana Barea Roldan; Abderaouf Selmi; Özlem Türeci; Ugur Sahin
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.